earnings
confidence high
sentiment positive
materiality 0.75
Royalty Pharma Q1 Portfolio Receipts $839M (+17% YoY); raises FY2025 guidance
Royalty Pharma plc
2025-Q1 EPS reported
$0.55
revenue$568,247,000
- Royalty Receipts grew 12% to $788M; cystic fibrosis franchise, Trelegy, Xtandi drove growth.
- Raised FY2025 Portfolio Receipts guidance to $2,975M-$3,125M (prior $2,900M-$3,050M).
- Repurchased 23M shares for $723M under new $3B buyback program.
- Internalization of manager RP Management ($1.1B) vote May 12, closing expected Q2 2025.
- Biogen R&D funding for litifilimab (up to $250M); $50M upfront in Q1.